Implantable Transvenous Cardioverter-Defibrillators
Implantable cardioverter-defibrillators have pro- vided protection against sudden death in patients resuscitated from cardiac arrest. Objections to the use of implantable antiarrhythmia devices continue, however, because of concerns related to expense and to operative morbidity and mortality associated with the application of epicardial lead systems. Perioperative complications have been in the range of 15-42% and perioperative mortality as high as 8%.1-6 Alternative therapies for cardiac arrest survivors fare no better. Direct surgical treatment of ventricular tachycardia (VT) and ventricular fibrillation (VF) are used with decreasing frequency because of the limited clinical applicability of such surgery and because of the high surgical morbidity and mortality.7-14 Catheter-mediated ablation procedures are also limited in scope and are even less successful. [15] [16] [17] [18] [19] [20] [21] [22] [23] Antiarrhythmic drug treatment of VT and VF also has limitations. Increasing reports of proarrhythmia or decreased survival with antiarrhythmic drug use has led to a reappraisal of the suitability of drug therapy in patients with VT 
Methods

Patient Population
After providing informed verbal and written consent for this protocol, implantation of a transvenous defibrillator was attempted under general anesthesia in 84 patients; 41 survived primary VF, 27 sustained VT, and 16 both VF and VT. Device implantation was performed after antiarrhythmics had been discontinued at least five half-lives except in the case of 16 patients on amiodarone. Amiodarone was discontinued as long as practically possible before surgery. The mean time period from discontinuation of amiodarone to device implantation was 29+32 days (range, 2-120 days). Devices were implanted consecutively except in the first 10 patients, in whom device availability limited use to those who would benefit most from a transvenous lead system. Transvenous devices were not used in patients requiring concomitant cardiac surgery. It should be noted that the first 16 of the 84 patients have been described in an earlier report. 40 
Lead Systems
The transvenous lead system consisted of two or three leads, depending on outcome during lead system evaluation. A 110-cm, 10.5F right ventricular (RV) tripolar pace, sense, and defibrillation lead (Medtronic model 6966) electrode was used in all of the configurations. This lead had an active fixation cathodal screw-in electrode for pacing and, 1.5 cm proximally, an anodal ring electrode for bipolar sensing. The lead tip was positioned deep into the RV apex. Proximal to the two sensing electrodes was a 5-cm-long platinum-iridium coil electrode used for cardioversion and defibrillation. Because of the RV catheter French size and concern over first rib-clavicular crush syndrome, the RV lead was preferentially inserted into the left cephalic vein. The left subclavian vein was cannulated using Seldinger technique only when the cephalic vein was not available.
A 110-cm, 6 .5F catheter (Medtronic model 6963) had a 5-cm-long coil electrode that could be positioned in nary sinus (CS). This lead was inserted using Seldinger technique cannulation of the left subclavian vein.
A third lead available for use was a 40-cm2 subcutaneous chest patch (CP) electrode (Medtronic model 6999). Its precise subcutaneous location over the left lateral thorax was directed by the results of intraoperative defibrillation testing. As described below, in some difficult-to-defibrillate patients, a roving chest paddle electrode of comparable surface area to the subcutaneous CP electrode was used to explore transvenous defibrillation efficacy before making the surgical incision and committing to a permanent lead system. 41 All transvenous leads were tunneled from their thoracic insertion sites to an abdominal pocket for connection to the pulse generator. The manner in which these leads were used depended on anatomic considerations, our previous experience, and/or the results of intraoperative defibrillation testing.42 '43 Electrode Position and Defibrillation Technique
The transvenous lead system and defibrillation pulsing technique chosen for use were those available with a tiered-therapy multiprogrammable antiarrhythmia device (Medtronic model 7217B PCD). This device was capable of delivering monophasic truncated exponential shocks from a 120-,F capacitor via single-pathway, dual-pathway simultaneous, or dual-pathway sequential pulsing at a maximum output of 34 J.33,36,37,39A40,4
The pulsing methods described in this section represent our most recent experience derived from 2 years of cumulative efforts at streamlining and improving transvenous implant techniques. The approach described herein delineates our most recent implant technique that we believe is efficient, relatively easy, and most likely to keep the number of incisions to two instead of three. These methods are summarized in Figures 1 and  2 . The approaches used early in our experience have been described previously.40 '43 Initial defibrillation testing began by examining defibrillation efficacy with a 15-J sequential pulse technique using a RV electrode as a common cathode, a high SVC left subclavian vein electrode as the first anode, and a high CP electrode beneath the left clavicle as the second anode. The locations of the electrodes are shown in Figure 1A . The subcutaneous CP electrode is much higher than previously reported, as is the SVC electrode, which was inserted such that its tip lay in the midline.30-39 If defibrillation was successful with the 15-J sequential pulse, the energy setting was decreased, and VF was reinduced until the defibrillation threshold was found using the technique defined below in the section, "Safety Concerns and Defibrillation Testing." If defibrillation was unsuccessful with the sequential pulse method at 15 J, a rescue pulse was delivered, and testing was repeated 3 minutes later using a 15-J simultaneous pulse technique via the same lead system in the same location with the same electrode polarity. If 15-J simultaneous pulsing failed, single-pathway pulsing, RV to SVC or RV to CP, was attempted only when the pulsing resistance, as determined by a 2-J sinus rhythm test pulse, was low enough to allow delivery of a 65% tilt pulse in this device that had a maximum pulse width of 8.1 msec. 45 If defibrillation was unsuccessful at 15 J with the either the high superior vena cava (SVC) or the coroinitial lead location shown in Figure 1A , the CS was FIGURE 1 . Chest x-rays of representative transvenous defibrillator lead systems are shown on this page and facing page. Posteroanterior views are shown in left panels; lateral views are shown in right panels. Panel A: A 6.5F defibrillation lead was positioned into the superior vena cava (SVC) for dual pathway defibrillation using the right ventricular (RV) electrode as the common cathode, the high SVC/left subclavian vein electrode as the first anode, and the chest patch (CP) electrode in the high left anterolateral thorax as the second anode. Panel B: Dual pathway defibrillation with the 6.5F lead positioned distally in the coronary sinus (CS) with the RV electrode as the common cathode, the CS electrode as the first anode, and the CP electrode in the high left anterolateral thorax as the second anode. Panel C: Dual pathway defibrillation with the 6.5F lead positioned distally in the CS with the CS electrode as the common cathode, the RV electrode as the first anode, and the CP electrode in the low left lateral thorax as the second anode. Panel D: Dual pathway defibrillation with the 6.5F lead positioned proximally in the CS with the CP electrode in the low left lateral thorax as the common cathode, the CS electrode as the first anode, and the RV electrode as the second anode.
cannulated with the 6.5F lead that had previously been positioned high in the SVC. When the CS could be cannulated, every effort was made to position the lead distally so that the tip of the electrode was positioned at the left lateral margin of the cardiac silhouette, as visualized fluoroscopically.
With the lead positioned distally in the CS ( Figure  1B ) a 15-J dual pathway sequential pulse was tested during VF using the RV electrode as the common cathode, the CS electrode as the first anode, and the CP electrode as the second anode. If defibrillation was unsuccessful with the sequential pulse method at 15 J, testing was repeated using a 15-J simultaneous pulse technique via the same lead system in the same location. As above, if either pulsing technique was successful at 15 J, then the defibrillation threshold (DFT) was measured. As with the first lead system tested, shown in Figure 1A , the CP electrode for this second lead system was positioned high on the thorax via the same infraclavicular incision used for accessing the cephalic and subclavian veins.
The next method tested was dual-pathway sequential pulsing, and, if necessary, dual-pathway simultaneous pulsing using the CS electrode as the common cathode, the RV electrode as the first anode, and the CP electrode as the second anode. Again, the use of this method required that the 6.5F lead be positioned distally in the CS. The CP electrode position, on the other hand, was now moved lower on the thorax, as shown in Figure 1C , in order to better direct current through the ventricular myocardium from the CS to the CP.43 This pulsing method also differed from the other methods described above in that it was necessary to use a chest paddle instead of the actual subcutaneous electrode during defibrillation testing until it could be demonstrated that defibrillation was feasible with this approach. Otherwise, an unnecessary incision might have been made. If defibrillation at 15 J was successful with the cutaneous paddle, an incision was made in the inframammary fold, and the actual subcutaneous patch was placed in the same location as the cutaneous paddle. Defibrillation testing was then repeated using the permanent subcutaneous patch lead. It was this latter DFT value, not that obtained with the roving paddle electrode, that was recorded as the DFT.
If the 6.5F lead could only be positioned proximally in the CS, as shown in Figure iD was 15-J sequential pulse defibrillation using the CP electrode as the common cathode, the CS electrode as the first anode, and the RV electrode as the second anode. If sequential pulse defibrillation at 15 J was unsuccessful, simultaneous pulse defibrillation at 15 J was tested. As with the previous method, where the distal CS electrode was used as a common cathode, the CP location was lower on the thorax than when the RV electrode was used as the common cathode, i.e., the position shown in Figure 1B . Also, as with the method used in Figure 1C , a roving chest paddle was used to simulate the subcutaneous patch before making an inframammary incision for patch placement. If the results were favorable with the roving chest paddle, the incision was made, the subcutaneous patch electrode placed, and the DFT was remeasured. It was this last DFT measurement with the permanent subcutaneous patch lead that was included in our data base.
If 15-J pulses were unsuccessful with any of the methods described above, defibrillation with a 20-J pulse was deemed acceptable before abandoning the transvenous approach. A single successful defibrillation at 20 J was deemed sufficient to allow implantation. If transvenous defibrillation was not possible at 20 J, the patient was allowed to recover from the anesthesia and the stress of multiple VF inductions and was brought back to the operating room 2-3 days later for an epicardial implant. A diagram delineating the sequence of defibrillation testing is shown in Figure 2 .
Safety Concerns and Defibrillation Testing
All patients underwent transvenous defibrillator testing under general anesthesia in a standard cardiac surgery suite. Anesthetic agents that depressed myocardial function were avoided. Arterial pressure was monitored and maintained before and after VF inductions at a mean value of 80-100 mm Hg, using phenylephrine if necessary. Cardiac stimulants were not used to avoid proarrhythmia and to minimize pharmacological alterations of the DFT.
Before VF induction and DFT testing, the integrity of all electrical connections was confirmed by recording the voltage and current waveforms during the delivery test pulses into normal sinus rhythm.40. Upon confirming that all necessary electrical connections were secure, VF was induced, and the first transvenous defibrillation test began with a 15-J pulse delivered 10 seconds after VF onset inclusive of the time period during which alternating current was applied. 46 If the transvenous pulse was unsuccessful, a 100-200-J transthoracic rescue pulse was delivered immediately via a precharged external defibrillator (Physio-Control LIFEPAK 6s), thereby minimizing VF duration to no more than 12-13 seconds. Prompt transthoracic defibrillation was possible via a switch system that permitted dual function for the anterolateral chest paddle electrode.41 With a change of the switch, the chest electrode that could be used for simulating the subcutaneous patch electrode for transvenous defibrillation could be recruited for transthoracic defibrillation in conjunction with a preapplied large posterior R2 patch electrode (Darox Corporation) placed between the right scapula and the spine.
After a minimum waiting period of 3 minutes between VF inductions, pulse output was incremented or decremented, depending on transvenous shock failure or success. Pulse energies were changed in 5 -J steps between energies of 10-30 J and in 2.5-J steps for pulsing energies below 10 J. Between each induction and termination of VF, care was taken to ensure that ECG ST-T segments and QRS duration as well as arterial pressure had returned to baseline values before VF was reinitiated. Note that the DFT was only measured for pulsing methods that were successful at 15 J or less, or, if none could be found, a 20-J threshold was sought, and pulsing energy levels were incremented rather than decremented as described above.
The transvenous DFT was defined as the lowest pulse amplitude that could successfully terminate VF 10 seconds after its initiation. 46 Because of the limitations of repetitive induction and termination of VF in humans, the DFT was measured only once. Even with these clinical restraints, the number of VF inductions and terminations required to find a suitable implant configuration was 9.9+4.0 (range, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . For implantation of the transvenous defibrillator, the DFT had to occur with a defibrillator setting of 20 J or less. In practice, however, five patients were subsequently found to have had DFTs slightly above 20 J when their voltage waveforms were analyzed postoperatively and the stored energy of the defibrillation pulse was precisely measured using techniques previously described.47 Selection 
of Detection Parameters
Once the device had been implanted, arrhythmia detection parameters could be selected to address specific clinical circumstances. Detection criteria varied depending on whether one was endeavoring to detect VF or both VT and VF.40,448-5l When using the VT detection algorithm, device identification of VT was dependent on counting consecutive beats having a cycle length less than or equal to a programmable criterion termed the tachycardia detection interval (TDI), programmable from 600 to 280 msec. The minimum number of intervals one could choose to satisfy the VT detection criterion (NID) ranged from four to 52. The continued presence of VT after charging was required of synchronized 2-J transvenous and 5-J transthoracic before delivery of VT cardioversion therapy. 
Implant Data
Successful transvenous lead system implantation was possible in 80 of 84 patients (95%). The total time in the operating room for implantation ranged between 150 and 345 minutes, with a mean time of 247±41 minutes. It should be recognized that some of this time was research time for various defibrillation protocols unrelated to the actual implantation of the cardioverterdefibrillator examined in this study. Thus, the total time for implantation would probably be less than the time provided above. Because the research and clinical procedures overlapped, it was not possible to separate research from clinical time.
The defibrillation lead system and pulsing technique ultimately used varied substantially from patient to patient ( Table 2 ). The majority of patients, 49 (61%) received a RV-CS-CP system. In the remaining 31 patients, a RV-SVC-CP system was used in 29 (36%), a RV-CP system was used in one (1%), and a RV-CSepicardial patch (CPI model 0041) was used in one (1%). This last patient had developed a RV epicardial defibrillation patch fracture in a lead system inserted 4 years earlier.
The measured delivered energy DFT at the time of implantation in the 80 successfully implanted patients was 10.9±4.8 J, with a range of 1.4-21.6 J. The DFT in those patients with RV-CS-CP lead systems was 11.3±4.7 J. The DFT for those with RV-SVC-CP lead systems was 10.8±4.7 J. The DFT for the patient with a RV-CP lead system was 6.4 J. The DFT for the patient with a RV-CS-epicardial patch system was 11.2 J. Because the RV-CS-CP lead system was usually tested after the RV-SVC-CP lead system failed, a valid comparison of relative lead system efficacy cannot be made in this study.
Four of the 84 patients in this study did not satisfy the DFT implant criterion. In one patient (No. 12), no ready explanation for a high-energy transvenous DFT could be found. He had an old diaphragmatic myocardial infarction, weighed 176 lb, and had an ejection fraction of 42%. Fifteen different transvenous pulsing methods had been evaluated in this patient, but no method would result in a DFT <20 J. This patient subsequently underwent implantation of an epicardial lead system 2 days later, where he happened to manifest a high epicardial DFT as well. Sequential pulse defibrillation using three large epicardial patches yielded a DFT of 13.8 J, a value substantially above our mean three-patch epicardial DFT of 4.1±3.1 J. 40 The Figure 3 .) The epicardial DFT in this patient was 20 J using three large patches.
Failure to insert a transvenous defibrillator was not apparently related to age, type of heart disease, index arrhythmia, QRS duration, heart failure class, or left ventricular ejection fraction. In addition, no correlation was demonstrated between the implant DFT and the left ventricular ejection fraction (r= -0.21, Figure 3) .
The pacing thresholds with this transvenous tieredtherapy device were comparable to standard pacing thresholds for endocardial bradycardia pacemakers and superior to those typically observed with epicardial lead systems.57-61 The pacing threshold at a pulse width of 0.5 msec was 0.96+0.39 V (range, 0.3-2.8 V). The sinus rhythm R waves similarly were satisfactory, measuring 16.4±6.4 mV (range, 6.0-25.0 mV) at the time of implantation.
Thirteen of 80 patients (16%) receiving a transvenous device were spared the need for insertion of a separate bradycardia pacemaker because of the device's capability of providing backup demand VVI (ventricular inhibited) pacing. All of these 13 patients had episodic heart block and required only intermittent bradycardia pacemaker support.
In-Hospital Follow-up and Short-term Complications
The immediate postoperative course was relatively uneventful. All patients were awake and extubated in the operating room at the end of the surgery. In addition, all patients were able to ambulate within 24 hours. The mean hospital stay was 6.0±2. 4 CS lead dislodgments occurred within the first week after implant in five patients. In three patients, the CS leads would not stay in position despite reapplication. Ultimately, repositioning of the lead into the SVC resulted in satisfactory defibrillation, albeit at higher energy than with CS lead positions in these three cases. In two other patients with CS lead dislodgments, the leads were restored to their previous CS locations upon repositioning, remaining in place chronically thereafter. In these last two cases, CS lead dislodgment appeared to be a consequence of too-loosely-applied anchoring sleeves, as observed at the time of lead repositioning 1 day and 5 days after implant.
RV lead dislodgment occurred in three patients, one acutely and two subacutely. In two patients, the leads withdrew into the proximal RV and, in one case, the lead withdrew into the right atrium. One dislodgment occurred 3 days after our first transvenous implant and was due to a too-loosely-applied anchoring sleeve. The lead was better secured upon repositioning and remained in place thereafter. In the other two patients, the RV lead was noted to have dislodged within 6 weeks after implantation. In one case, the patient felt a snap beneath her left clavicle while swinging a croquet mallet. At the time of lead repositioning, the anchoring sleeve was found to be unsecured to the underlying fascia, presumably avulsed from the tissue during swinging of the croquet mallet. In the other patient, RV lead dislodgment occurred without apparent provocation and appeared to be a consequence of inadequate lead stabilization to the underlying pectoralis fascia at the site of the anchoring sleeve. All patients have since had two anchoring sleeves applied on either end of a redundant loop of coil intended to relieve tension on the leads.
Long-term Follow-up: Arrhythmia Detection and Therapy
In the follow-up period of 11±7 months (range, 1-34 months), 31 of the 80 patients (39%) were treated by their device. Four patients had "VT" only detected by their device, 11 had "VF" only detected by their device, and 16 had both "VT" and "VF" detected by their device. The antiarrhythmia device detected 471 episodes of tachyarrhythmia as "VT" in 20 of the 80 patients. An additional 120 episodes of tachyarrhythmia been described after implantation of epicardial lead were detected as 'TIF' in 27 of the 80 patients. LVEF, left ventricular ejection fraction; Arr, arrhythmia; VF, ventricular fibrillation; VT, ventricular tachycardia; CAD, coronary artery disease; PED, primary electrical disease; CHD, congenital heart disease; RVD, right ventricular dysplasia; HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy; LOTS, long QT syndrome; CM, cardiomyopathy. *Patients failing transvenous defibrillator implant. The number of "VT" episodes per patient in the entire population ranged from 0 to 212. Upon review of the device memory and available clinical data, 44 of the 471 "VT" episodes (9%) occurring in three patients were determined to be inappropriately treated AF associated with a rapid ventricular response and three of the 471 "VT" episodes (1%), also occurring in three patients, were sinus tachycardia. Thus, 424 of 471 "VT" episodes (90%) were considered episodes of true clinical VT.
Of the three patients with the 44 episodes of "VT" that were shown to be inappropriately treated AF, the stability function was not initially programmed in one. Subsequent activation of the stability algorithm prevented further inappropriate therapies. In the other two patients, the stability algorithm had been too liberally programmed to 80 msec, which did not prevent inappropriate detection of AF. With a more rigorous detection algorithm, VT therapy for AF no longer occurred.
In addition to the three patients described above, there were eight more patients with known AF who had the stability criterion activated prophylactically and had no inappropriate VT therapies for AF.
The chronic interval stability parameter was ultimately programmed to 30 msec in one, 40 msec in two, 50 msec in one, and 60 msec in seven patients. The associated number of consecutive intervals required to detect VT was programmed from 16 to 24. It should be noted that these parameters reflect the final programmed values and not initial attempts to prevent AF detection with the stability criterion, which was usually programmed to 60 msec initially, sometimes 80 msec, and adjusted to shorter intervals, depending on outcome. In practice, stability values of 80 msec were too wide. Moreover, some patients not only required a short stability criterion but the added advantage of a longer accounting for the inappropriate therapy of sinus In the three patients with an episode of sinus tachycardia. Reprogramming the TDI to shorter intertachycardia treated as "VT," reprogramming of the vals corrected the problem and did not interfere with VT detection criterion to a shorter cycle length pre-VT detection as the VT rate also increased off of vented subsequent inappropriate treatment of sinus amiodarone.
tachycardia. All three of these patients had been on
Of the 424 of 471 episodes of "VT" that were amiodarone before device implantation and had sinus designated as true VT in 20 patients, the mean VT cycle (range, 280-490 msec) . Note that these VT cycle lengths include only those VT episodes that fell within the VT detection zone. Shorter cycle length VT episodes were also present in this population but fell into the VF detection zone and therefore are not reflected in the 352±70-msec figure. (See VF data below.) Antitachycardia pacing therapies were successful in 371 (88%) of the 424 VT episodes identified above. (See example shown in Figure 4 .) Antitachycardia pacing was programmed as a ramp in all except one of the patients in whom pacing therapy was delivered. Burst antitachycardia pacing was used only in patients with relatively slow VT. Low-energy cardioversion, defined as <1.0 J, was successful in terminating VT in the four episodes (1%) in which it was used. High-energy cardioversion was required in only 34 of the 424 episodes (8%) of VT occurring in the VT detection zone.
Thirteen episodes of VT (3%) were accelerated by antitachycardia pacing into the "VF" detection zone. One of these episodes was an acceleration of a slower VT (280 msec) into a faster VT (240 msec). This faster VT was subsequently cardioverted with a high-energy "VF" therapy. The other 12 episodes of monomorphic VT were accelerated into true VF. In each case, a high-energy pulse subsequently terminated VF. All 12 episodes accelerated as a consequence of overdrive autodecremental antitachycardia (ramp) pacing. In 26 patients, the device treated 120 spontaneous tachyarrhythmias as "VF." These figures include the 13 episodes that were a consequence of antitachycardia pacing acceleration of monomorphic VT. True VF was determined to be present in 25 of these 120 episodes (21%). Rapid monomorphic VT with cycle lengths falling within the fibrillation detection zone accounted for 72 of these 120 episodes (60%). Wholly 23 of these 72 episodes of rapid monomorphic VT occurred in one patient. The VT cycle length for these episodes of rapid VT detected as "VF" was 269±40 msec (range, 240-310 msec). All episodes of VF as well as rapid monomorphic VT were successfully treated in each case. Monomorphic VT or VF did not go undetected in any patient.
The remaining 23 "VF" therapies were delivered for paroxysmal AF in two patients. One patient accounted for 22 of these 23 episodes, having been repetitively shocked over the course of several hours. In this patient's case, the fibrillation detection interval of 320 msec had been programmed too liberally. (Note that the stability criterion applies only to VT detection and not to VF detection.) The addition of diltiazem to this patient's drug regimen sufficiently slowed AV conduction to prevent discharge into recurrent AF thereafter. No morbidity was associated with inappropriate therapy of AF except for the discomfort of repetitive shocks.
Long-term Follow-up: Antiarrhythmic Drugs Antiarrhythmic drugs were used in only eight of the 80 patients (10%). Two patients were started on amio- darone and two were started on dilantin several months after device implantation, in an effort to control recurrent episodes of VT. Two patients were started on diltiazem and one was started on procainamide after operation for control of a rapid ventricular response associated with recurrent AF. One patient received mexiletine as part of an unrelated protocol in which antiarrhythmic drug administration was not associated with AF or device failure to control VT or VF events. 65 Antiarrhythmic drugs could be withdrawn as a consequence of device implantation in 33 of the 80 patients (41%). These patients had either developed drug side effects or had failed antiarrhythmic drug suppression of their VT/VF either clinically or by electrophysiological testing before device implantation. The device functioned sufficiently well that these patients no longer needed to take medications.
An additional 39 patients (49%) never received antiarrhythmic drugs. Each of these 39 patients presented directly to our institution for transvenous cardioverterdefibrillator implantation shortly after their index cardiac arrhythmia.
Long-term Follow-up: Complications
Six patients developed complications after hospital discharge, not including those with lead dislodgments reviewed earlier in the section on "In-Hospital Follow-up and Short-term Complications." Two of the six complications were asymptomatic left subclavian vein thromboses observed during routine follow-up 1 month and 2 months after surgery. One patient on coumadin developed a subcutaneous patch pocket hematoma 3 weeks after implantation. A fourth patient developed an abdominal pulse generator pocket infection 6 weeks after implantation that required system removal. Both leads and pulse generator were removed in this patient as a conservative management approach, although the only evidence of infection was in the pulse generator pocket. The patient was placed on amiodarone while awaiting system reinsertion. A fifth patient developed a subcutaneous patch cable fracture at the point where the cable passed over the rib cage to the abdominal pocket. The fractured lead was identified during a routine chest x-ray. No explanation could be found to explain the fracture. The lead was replaced uneventfully. The sixth complication was identified during a routine chest x-ray 5 months after implantation. The patient was a "twiddler" who thought that her habit of rotating her pulse generator would be harmless. The leads were grossly intertwined like a triple helix because of unidirectional twiddling. The leads were sufficiently twisted so that lead redundancy in the heart had been eliminated. Consequently, the pocket was opened, the helix was unwound, and lead redundancy was restored. Long-term Follow-up: Survival Total patient survival is shown in Figure 5 . The present study has also demonstrated a decrease in the number of perioperative complications often seen with epicardial lead systems. For example, coronary artery erosions, intrathoracic bleeding or infections, decompensated heart failure, cerebrovascular accidents, pericardial effusions and tamponade, pericarditis, and phrenic nerve injuries have been observed in patients receiving epicardial systems.2-6 Although the incidence of each of these complications is small for epicardial lead systems, the consequences of any one of these can be serious. In this study, only two patients had comparable complications: an asymptomatic, hemodynamically insignificant pericardial effusion in one and a pulse generator pocket infection in another.
Another sequela of epicardial lead systems not observed in our transvenous population is the phenomenon of postoperative "electrical storm."61-63 In a small but significant subset of patients undergoing insertion of an epicardial cardioverter-defibrillator, a flurry of postoperative atrial or ventricular arrhythmias can lead to multiple shocks. In the awake patient recovering from a sternotomy or thoracotomy, these high-energy shocks can be very painful. In certain circumstances, repetitive inappropriate shocks, especially for AF, can lead to cardiac arrest and even death. At minimum, repetitive shocks are traumatic psychologically.
In an era of increasing cost-consciousness in health care, 75 
